FRIDAY, May 19, 2023 (HealthDay News) -- Patients with Crohn’s disease have a new treatment option, following U.S. Food and Drug Administration approval of a pill called Rinvoq (upadacitinib).

Source: https://www.gjsentinel.com/lifestyle/health_and_wellness/fda-approves-first-pill-to-treat-moderate-to-severe-crohns-disease/article_8b02bbbc-c002-5da2-bca2-17218462c453.html

Skyrizi and Rinvoq are now on pace to deliver more than $17.5 billion in combined sales, risk adjusted sales in 2025, well above our previous expectations.

Source: https://seekingalpha.com/article/4570975-abbvie-modelling-post-humira-bull-case-2030-bright-outlook?source=feed_all_articles